Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria

Introduction: Ceragenin CSA‐13 is a bile‐acid‐based mimic of endogenous antimicrobial peptides and shares a mechanism of action with many of these antimicrobial agents. Because CSA‐13 is not peptide based, it is not a substrate for the proteases that are found in the oral cavity, which are capable of degrading antimicrobial peptides. Furthermore, the simplicity of the ceragenins makes them easier to prepare and purify than antimicrobial peptides. In this study, we examined the antimicrobial activities of CSA‐13 against oral pathogens and found that this compound was bactericidal against all of the strains tested. Methods: The strains used were isolates of Streptococcus mutans and Porphyromonas species. Minimum inhibitory concentrations (MIC) were determined using agar dilution methods. In susceptibility testing, viable counts were determined after incubation with CSA‐13. Results: CSA‐13 was potent against all 23 strains tested with MICs of 1–8 μg/ml for S. mutans and 1–16 μg/ml for 24 strains of the genus Porphyromonas. The MIC50 was 2 and the MIC90 was 8 μg/ml for S. mutans. MIC ranges for protease‐positive P. gingivalis and P. cangingivaliswere 2–16 μg/ml, and 1–2 μg/ml for protease‐negative P. circumdentaria. CSA‐13 interacted with lipopolysaccharide‐sensitized erythrocytes at a concentration of 5.0–20.0 μg/ml. Conclusion: CSA‐13 displays broad‐spectrum activity against cariogenic and periodontopathic bacteria. CSA‐13 was effective against protease‐positive Porphyromonas. It was shown to bind to erythrocytes coated with lipopolysaccharide and lipoteichoic acid from diverse bacterial strains. These results suggest that CSA‐13 may be useful for the prevention and treatment of oral microbial diseases.